The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 243 results:
Author Title Type [ Year(Asc)]
Filters: Author is Karagiannis, Asterios  [Clear All Filters]
2019
Koutsampasopoulos, K., Vogiatzis I., Ziakas A., Papadopoulos C., Imprialos K. P., Stavropoulos K., et al. (2019).  Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure.. J Sex Med.
Polyzos, S. A., Perakakis N., Boutari C., Kountouras J., Ghaly W., Anastasilakis A. D., et al. (2019).  Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD.. J Clin Endocrinol Metab.
Patoulias, D., Katsimardou A., Kalogirou M-S., Karagiannis A., & Doumas M. (2019).  Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?. Dig Liver Dis.
2018
Georgianou, E., Georgianos P. I., Petidis K., Athyros V. G., Sarafidis P. A., & Karagiannis A. (2018).  Antihypertensive therapy in acute ischemic stroke: where do we stand?. J Hum Hypertens. 32(12), 799-807.
Athyros, V. G., Sachinidis A. G., Zografou I., Simoulidou E., Piperidou A., Stavropoulos N., et al. (2018).  Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.. Curr Pharm Des. 24(46), 5542-5547.
Athyros, V. G., Doumas M., Imprialos K. P., Stavropoulos K., Georgianou E., Katsimardou A., et al. (2018).  Diabetes and lipid metabolism.. Hormones (Athens). 17(1), 61-67.
Anagnostis, P., Paschou S. A., Goulis D. G., Athyros V. G., & Karagiannis A. (2018).  Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?. Maturitas. 108, 45-52.
Anagnostis, P., Siolos P., Christou K., Gkekas N. K., Kosmidou N., Athyros V. G., et al. (2018).  The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data.. Hormones (Athens). 17(1), 83-95.
Mitsiou, E., Boutari C., Kotsis V., Georgianou E., Doumas M., Karagiannis A., et al. (2018).  Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension.. Curr Vasc Pharmacol. 16(4), 393-400.
Upadhyay, J., Polyzos S. A., Perakakis N., Thakkar B., Paschou S. A., Katsiki N., et al. (2018).  Pharmacotherapy of type 2 diabetes: An update.. Metabolism. 78, 13-42.
Stavropoulos, K., Imprialos K. P., Katsiki N., Petidis K., Kamparoudis A., Petras P., et al. (2018).  Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. J Clin Hypertens (Greenwich). 20(5), 942-948.
Doumas, M., Stavropoulos K., Imprialos K. P., Athyros V. G., & Karagiannis A. (2018).  Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. J Clin Hypertens (Greenwich). 20(4), 634-636.
Patoulias, D., Manafis A., Mitas C., Avranas K., Lales G., Zografou I., et al. (2018).  Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.. Cardiovasc Hematol Disord Drug Targets. 18(2), 139-146.
Stavropoulos, K., Imprialos K. P., Doumas M., Athyros V. G., & Karagiannis A. (2018).  Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. J Hypertens. 36(3), 701.
2017
Theocharidou, E., Gossios T. D., & Karagiannis A. (2017).  Acute Coronary Syndrome in Patients With Inflammatory Bowel Diseases: The Plaque and the Thrombus.. Angiology. 68(10), 843-844.
Doumas, M., Stavropoulos K. V., Boutari C., Imprialos K. P., & Karagiannis A. (2017).  Blood pressure and cardiovascular outcomes: a closer look.. Lancet. 389(10076), 1295-1296.
Athyros, V. G., Tziomalos K., Doumas M., Sfikas G., & Karagiannis A. (2017).  The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.. Curr Pharm Des. 23(10), 1477-1483.
Imprialos, K. P., Stavropoulos K., Doumas M., Karagiannis A., & Athyros V. G. (2017).  The effect of SGLT2 inhibitors on cardiovascular events and renal function.. Expert Rev Clin Pharmacol. 10(11), 1251-1261.
Athyros, V. G., Papageorgiou A., Athyrou V., & Karagiannis A. (2017).  Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Tre. J Clin Lipidol. 11(1), 306-307.
Tsaganos, T., Tseti I. K., Tziolos N., Soumelas G-S., Koupetori M., Pyrpasopoulou A., et al. (2017).  Randomized, controlled, multicentre clinical trial of the antipyretic effect of intravenous paracetamol in patients admitted to hospital with infection.. Br J Clin Pharmacol. 83(4), 742-750.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2017).  Semaglutide, lipid-lowering drugs, and NAFLD.. Lancet Diabetes Endocrinol. 5(5), 329-330.
Imprialos, K., Faselis C., Boutari C., Stavropoulos K., Athyros V., Karagiannis A., et al. (2017).  SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.. Curr Pharm Des. 23(10), 1510-1521.
Athyros, V. G., Alexandrides T. K., Bilianou H., Cholongitas E., Doumas M., Ganotakis E. S., et al. (2017).  The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.. Metabolism. 71, 17-32.
Athyros, V. G., Alexandrides T. K., Bilianou H., Cholongitas E., Doumas M., Ganotakis E. S., et al. (2017).  The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 71, 17 - 32.
2016
Athyros, V. Gabriel, Doumas M., & Karagiannis A. (2016).  Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action.. Indian Heart J. 68(5), 596-598.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.